Literature DB >> 32119598

Neoadjuvant or Adjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer: Which Is Preferred?

Eileen M O'Reilly1,2, Cristina Ferrone3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32119598      PMCID: PMC7255981          DOI: 10.1200/JCO.19.03318

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  20 in total

1.  Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement.

Authors:  Ross A Abrams; Andrew M Lowy; Eileen M O'Reilly; Robert A Wolff; Vincent J Picozzi; Peter W T Pisters
Journal:  Ann Surg Oncol       Date:  2009-04-24       Impact factor: 5.344

2.  Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score Adjusted Analysis.

Authors:  Jordan M Cloyd; Hsiang-Chun Chen; Xuemei Wang; Ching-Wei D Tzeng; Michael P Kim; Thomas A Aloia; Jean-Nicolas Vauthey; Jeffrey E Lee; Matthew H G Katz
Journal:  Pancreas       Date:  2019-02       Impact factor: 3.327

3.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

Authors:  Thierry Conroy; Pascal Hammel; Mohamed Hebbar; Meher Ben Abdelghani; Alice C Wei; Jean-Luc Raoul; Laurence Choné; Eric Francois; Pascal Artru; James J Biagi; Thierry Lecomte; Eric Assenat; Roger Faroux; Marc Ychou; Julien Volet; Alain Sauvanet; Gilles Breysacher; Frédéric Di Fiore; Christine Cripps; Petr Kavan; Patrick Texereau; Karine Bouhier-Leporrier; Faiza Khemissa-Akouz; Jean-Louis Legoux; Béata Juzyna; Sophie Gourgou; Christopher J O'Callaghan; Claire Jouffroy-Zeller; Patrick Rat; David Malka; Florence Castan; Jean-Baptiste Bachet
Journal:  N Engl J Med       Date:  2018-12-20       Impact factor: 91.245

Review 4.  Pancreatic adenocarcinoma.

Authors:  David P Ryan; Theodore S Hong; Nabeel Bardeesy
Journal:  N Engl J Med       Date:  2014-09-11       Impact factor: 91.245

5.  Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.

Authors:  Janet E Murphy; Jennifer Y Wo; David P Ryan; Wenqing Jiang; Beow Y Yeap; Lorraine C Drapek; Lawrence S Blaszkowsky; Eunice L Kwak; Jill N Allen; Jeffrey W Clark; Jason E Faris; Andrew X Zhu; Lipika Goyal; Keith D Lillemoe; Thomas F DeLaney; Carlos Fernández-Del Castillo; Cristina R Ferrone; Theodore S Hong
Journal:  JAMA Oncol       Date:  2018-07-01       Impact factor: 31.777

6.  Pancreatic Adenocarcinoma, Version 1.2019.

Authors:  Margaret A Tempero; Mokenge P Malafa; E Gabriela Chiorean; Brian Czito; Courtney Scaife; Amol K Narang; Christos Fountzilas; Brian M Wolpin; Mahmoud Al-Hawary; Horacio Asbun; Stephen W Behrman; Al B Benson; Ellen Binder; Dana B Cardin; Charles Cha; Vincent Chung; Mary Dillhoff; Efrat Dotan; Cristina R Ferrone; George Fisher; Jeffrey Hardacre; William G Hawkins; Andrew H Ko; Noelle LoConte; Andrew M Lowy; Cassadie Moravek; Eric K Nakakura; Eileen M O'Reilly; Jorge Obando; Sushanth Reddy; Sarah Thayer; Robert A Wolff; Jennifer L Burns; Griselda Zuccarino-Catania
Journal:  J Natl Compr Canc Netw       Date:  2019-03-01       Impact factor: 11.908

7.  Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.

Authors:  Ali A Mokdad; Rebecca M Minter; Hong Zhu; Mathew M Augustine; Matthew R Porembka; Sam C Wang; Adam C Yopp; John C Mansour; Michael A Choti; Patricio M Polanco
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

8.  A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma.

Authors:  Susan Tsai; Kathleen K Christians; Ben George; Paul S Ritch; Kulwinder Dua; Abdul Khan; A Craig Mackinnon; Parag Tolat; Syed A Ahmad; William A Hall; Beth A Erickson; Douglas B Evans
Journal:  Ann Surg       Date:  2018-10       Impact factor: 12.969

9.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Authors:  Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler
Journal:  N Engl J Med       Date:  2013-10-16       Impact factor: 91.245

10.  Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer.

Authors:  Ryan P Merkow; Karl Y Bilimoria; James S Tomlinson; Jennifer L Paruch; Jason B Fleming; Mark S Talamonti; Clifford Y Ko; David J Bentrem
Journal:  Ann Surg       Date:  2014-08       Impact factor: 12.969

View more
  7 in total

Review 1.  Pancreatic cancer treatment: better, but a long way to go.

Authors:  Robert J Torphy; Yuki Fujiwara; Richard D Schulick
Journal:  Surg Today       Date:  2020-05-30       Impact factor: 2.549

2.  Extended lymphadenectomy benefits patients with borderline resectable pancreatic head cancer-a single-center retrospective study.

Authors:  Jing Wang; Shao-Cheng Lyu; Ji-Qiao Zhu; Xian-Liang Li; Ren Lang; Qiang He
Journal:  Gland Surg       Date:  2021-10

3.  Pre-operative radiomics model for prognostication in resectable pancreatic adenocarcinoma with external validation.

Authors:  Gerard M Healy; Emmanuel Salinas-Miranda; Rahi Jain; Xin Dong; Dominik Deniffel; Ayelet Borgida; Ali Hosni; David T Ryan; Nwabundo Njeze; Anne McGuire; Kevin C Conlon; Jonathan D Dodd; Edmund Ronan Ryan; Robert C Grant; Steven Gallinger; Masoom A Haider
Journal:  Eur Radiol       Date:  2021-11-10       Impact factor: 7.034

4.  Roles and Clinical Significances of ATF6, EMC6, and APAF1 in Prognosis of Pancreatic Cancer.

Authors:  Wang Xiao; Rong-Chang Cao; Wan-Jun Yang; Jie-Hui Tan; Ruo-Qi Liu; He-Ping Kan; Lei Zhou; Na Zhang; Zhi-Ye Chen; Xue-Mei Chen; Jia Xu; Guo-Wei Zhang; Peng Shen
Journal:  Front Genet       Date:  2022-02-11       Impact factor: 4.599

5.  Perioperative Serum Scoring Systems Predict Early Recurrence and Poor Prognosis of Resectable Pancreatic Cancer.

Authors:  Shengnan Li; Gengpu Zhang; Yang Lu; Tiansuo Zhao; Chuntao Gao; Weishuai Liu; Yongjun Piao; Yanan Chen; Chongbiao Huang; Antao Chang; Jihui Hao
Journal:  Front Oncol       Date:  2022-02-21       Impact factor: 6.244

6.  CA19.9 Serum Level Predicts Lymph-Nodes Status in Resectable Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis.

Authors:  Alessandro Coppola; Vincenzo La Vaccara; Michele Fiore; Tommaso Farolfi; Sara Ramella; Silvia Angeletti; Roberto Coppola; Damiano Caputo
Journal:  Front Oncol       Date:  2021-05-27       Impact factor: 6.244

7.  Resected pancreatic adenocarcinoma: An Asian institution's experience.

Authors:  Kennedy Yao Yi Ng; Edwin Wei Xiang Chow; Bochao Jiang; Cindy Lim; Brian Kim Poh Goh; Ser Yee Lee; Jin Yao Teo; Damien Meng Yew Tan; Peng Chung Cheow; London Lucien Peng Jin Ooi; Pierce Kah Hoe Chow; Joycelyn Jie Xin Lee; Juinn Huar Kam; Ye Xin Koh; Prema Raj Jeyaraj; Ek Khoon Tan; Su Pin Choo; Chung Yip Chan; Alexander Yaw Fui Chung; David Tai
Journal:  Cancer Rep (Hoboken)       Date:  2021-05-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.